Biohaven Pharmaceutical Holding EPS - Earnings per Share 2016-2022 | BHVN
Biohaven Pharmaceutical Holding annual and quarterly earnings per share history from 2016 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Biohaven Pharmaceutical Holding EPS for the quarter ending March 31, 2022 was $-2.97, a 30.44% decline year-over-year.
- Biohaven Pharmaceutical Holding EPS for the twelve months ending March 31, 2022 was $-11.79, a 17.32% decline year-over-year.
- Biohaven Pharmaceutical Holding 2021 annual EPS was $-13.09, a 0.23% increase from 2020.
- Biohaven Pharmaceutical Holding 2020 annual EPS was $-13.06, a 19.71% increase from 2019.
- Biohaven Pharmaceutical Holding 2019 annual EPS was $-10.91, a 77.4% increase from 2018.
| Biohaven Pharmaceutical Holding Annual EPS |
| 2021 |
$-13.09 |
| 2020 |
$-13.06 |
| 2019 |
$-10.91 |
| 2018 |
$-6.15 |
| 2017 |
$-5.00 |
| 2016 |
$-5.05 |
| 2015 |
$-0.91 |
| Biohaven Pharmaceutical Holding Quarterly EPS |
| 2022-03-31 |
$-2.97 |
| 2021-12-31 |
$-2.96 |
| 2021-09-30 |
$-2.63 |
| 2021-06-30 |
$-3.23 |
| 2021-03-31 |
$-4.27 |
| 2020-12-31 |
$-3.64 |
| 2020-09-30 |
$-3.27 |
| 2020-06-30 |
$-3.08 |
| 2020-03-31 |
$-3.07 |
| 2019-12-31 |
$-2.79 |
| 2019-09-30 |
$-2.04 |
| 2019-06-30 |
$-4.67 |
| 2019-03-31 |
$-1.41 |
| 2018-12-31 |
$-1.29 |
| 2018-09-30 |
$-1.53 |
| 2018-06-30 |
$-1.01 |
| 2018-03-31 |
$-2.32 |
| 2017-12-31 |
$-0.29 |
| 2017-09-30 |
$-1.19 |
| 2017-06-30 |
$-1.78 |
| 2017-03-31 |
$-1.74 |
| 2016-12-31 |
$-2.09 |
| 2016-09-30 |
$-2.16 |
| 2016-06-30 |
$-0.55 |
| 2016-03-31 |
$-0.25 |
| 2015-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$9.944B |
$0.463B |
|
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
|
